4:12 PM Abstract No. 335 Safety and feasibility of transradial uterine fibroid embolization in an office-based lab

To assess the safety and feasibility of performing transradial uterine fibroid embolization (trUFE) in an office-based lab (OBL). A retrospective review was performed of all patients who underwent transradial uterine fibroid embolization (trUFE) at two office-based labs between June 2018 and July 2019. Data collected included demographic information, pertinent medical history, and procedural details (radiation exposure, length of procedure, time to discharge, complications). All procedures were performed under conscious sedation. Fluoroscopy and digital subtraction radiography were performed utilizing a portable C-arm (Philips Veradius). Ultrasound guidance for radial access was used in all cases. Bilateral Embolization was performed in all cases using embozene 500um and 700 μm particles. Approximately 8 mL of 1% lidocaine was administered to each uterine artery at the end of embolization. Postprocedural pain regimen consisted of fentanyl 25 mcg PRN and oxycodone/acetaminophen 5 mg/325 mg PRN. A total of 9 premenopausal women (mean age, 46.7 ± 4.9 years) underwent trUFE for symptomatic uterine fibroids. The mean procedure time was 68 minutes (range, 53-120) with the average fluoroscopy time of 22.1 minutes (range, 14.2-29.5). The average time to discharge was 4.4 hours. Median follow-up was 4 months. Clinical success measured by subjective relief in symptoms at 2-month follow-up was seen in 9/9 (100%) of the patients. There were no immediate or delayed postprocedural complications. One patient returned to the Emergency room 5 hours after discharge for pain management. Transradial uterine fibroid embolization can be safely performed in an office-based lab.